Delete search term


Quick navigation

Main navigation

Development of small-molecules targeting CD93-signaling for the treatment of leukemia

At a glance

  • Project leader : Prof. Dr. Rainer Riedl, Dr. Carsten Riether
  • Project team : Dr. Michael Brand
  • Project budget : CHF 483'000
  • Project status : completed
  • Funding partner : Innosuisse (Innovationsprojekt / Projekt Nr. 47219.1 IP-LS)
  • Project partner : Inselspital Bern
  • Contact person : Rainer Riedl


The aim of the current InnoSuisse application is to optimize small molecules, which were identified in a drug library screen to block CD93-signaling in LSCs and showed a positive clinical response, in order to develop lead candidates with a novel chemical scaffold and own IP to treat leukemia.